Cytosite Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cytosite Bio is a private, pre-revenue biotech founded in 2018 and based in San Diego, CA. The company's core innovation is a proprietary platform targeting granzyme B, which it leverages for two main applications: a PET imaging diagnostic (CSB-321) to provide early, mechanistic readouts of immunotherapy efficacy, and a preclinical radioimmunotherapy (CSB-421) designed to deliver radiation directly to immunologically active tumor sites. This dual-pronged strategy seeks to de-risk drug development and address a critical unmet need in treating immunotherapy-resistant cancers. The company is currently in the clinical stage with its diagnostic candidate and advancing its therapeutic through preclinical studies.

OncologyAutoimmune Diseases

Technology Platform

A proprietary platform targeting extracellular granzyme B for the development of radiodiagnostics and radioimmunotherapies. It leverages this key immune effector protein to visualize real-time immune activity and deliver targeted radiation to tumor microenvironments.

Opportunities

The platform addresses a critical unmet need in immuno-oncology: the lack of early, predictive biomarkers for treatment response and effective therapies for resistant patients.

Its diagnostic could de-risk and accelerate multi-billion dollar drug development pipelines, while its therapeutic targets a large, refractory patient population in the growing radioimmunotherapy market.

Risk Factors

The novel scientific approach carries significant clinical translation risk, as promising preclinical and early clinical data may not predict human efficacy.

As a first-in-class modality, the regulatory pathway is complex and uncertain.

The company is pre-revenue and faces intense competition in the crowded immuno-oncology space.

Competitive Landscape

Competition is fierce in both immuno-oncology biomarkers and therapeutics. Diagnostic rivals include companies developing PET tracers for other immune targets (e.g., CD8, PD-L1). Therapeutic competitors include large pharma with next-gen immunotherapies and a new wave of radiopharmaceutical companies. Cytosite's differentiation is its singular focus on granzyme B as a direct measure of cytotoxic immune activity.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →